Weight Loss Jabs: Could Addiction Treatment Be Next? | Rethinking Obesity & Willpower

The increasing acceptance of GLP-1 medications – often referred to as “weight-loss jabs” – is prompting a crucial re-evaluation of how society views both obesity and addiction. Recent research, including a large-scale study of US veterans, suggests these drugs may not only curb appetite but also reduce cravings more broadly, potentially impacting a range of addictive behaviors. This emerging understanding challenges long-held beliefs about willpower and personal responsibility when it comes to both weight management and substance use disorders.

Veterans Study Reveals Broad Impact on Addiction Risk

A study published March 4 in The BMJ, and highlighted by Military.com, analyzed electronic health records of over 606,000 US veterans with type 2 diabetes. Researchers at the Department of Veterans Affairs’ St. Louis Health Care System found that veterans taking GLP-1 medications (including Ozempic, Wegovy, Mounjaro, and Zepbound) had a lower risk of developing substance use disorders involving alcohol, opioids, nicotine, cocaine, cannabis, and other substances, compared to those taking SGLT2 inhibitors, another class of diabetes drugs. Importantly, for veterans already struggling with addiction, GLP-1 use was linked to reduced rates of hospitalization, overdose, and even death. The study also noted a 25% reduction in suicidal ideation among GLP-1 users – a particularly significant finding given previous concerns about a potential link between these drugs and increased suicide risk.

This isn’t an isolated finding. A separate analysis, detailed by Nature, examined the same VA data and found a 50% reduction in the risk of death from substance abuse among GLP-1 users. The consistency of these results across multiple substances, each with different biological mechanisms, is striking, according to Ziyad Al-Aly, a co-author of the study and a clinical epidemiologist at the VA St Louis Health Care System.

How Do These Drugs Work, and Why the Connection to Addiction?

GLP-1 medications work by mimicking a naturally occurring hormone that regulates blood sugar, promotes insulin release, and slows down gastric emptying. However, they also act on areas of the brain involved in satiation and reward. This suggests a potential overlap in the biological pathways underlying both food cravings and drug cravings. As David A Kessler, former head of the US Food and Drug Administration, argues in his book Diet, Drugs, and Dopamine, obesity isn’t simply a matter of willpower; it’s a biological process that can be targeted with medication. This perspective mirrors the shift in understanding surrounding addiction, which is now widely recognized as a chronic disease rather than a moral failing.

The Stigma Surrounding Weight Loss Medication

Despite the growing evidence of their potential benefits, GLP-1 agonists continue to face significant stigma. Many view using them for weight loss as a “cop-out,” suggesting individuals should address obesity through diet and exercise alone. This sentiment is reflected in articles questioning whether “weight loss is supposed to be easy” and in policies, such as those in Germany, that restrict coverage to diabetes treatment but not obesity. This contrasts sharply with the approach to addiction treatment, where medications like methadone and suboxone are widely accepted as valuable tools for managing opioid use disorder, even though they don’t represent complete abstinence.

The double standard is particularly noteworthy given the serious health consequences of obesity. The study of veterans underscores that obesity is a health condition deserving of medical intervention, just like addiction. The fact that approximately one in eight Americans and one in 20 people in the UK have already used a GLP-1 drug suggests a growing recognition of this need.

Potential Risks and Considerations

It’s crucial to acknowledge that GLP-1 agonists are not without potential downsides. They can be expensive, cause unpleasant side effects, and, as highlighted by recent reports, may carry a slightly increased risk of vision loss. Professor Chris Whitty, England’s chief medical officer, rightly emphasizes that these medications should not be seen as a substitute for broader public health policies promoting healthier food choices. A holistic approach to health, encompassing diet, exercise, and medical intervention when appropriate, remains essential.

What’s Next: Further Research and Shifting Perspectives

The findings from the VA study and others are prompting a call for larger clinical trials to definitively determine whether GLP-1 drugs can be effectively used to treat substance use disorders. Physicians are already reporting anecdotal evidence of patients experiencing reduced cravings for nicotine and alcohol while on these medications, but rigorous scientific investigation is needed to confirm these observations.

More broadly, the emerging evidence suggests a need to re-evaluate our societal attitudes towards both obesity and addiction. If we can move beyond moralizing and embrace a more pragmatic, biologically informed approach, we may unlock new and effective strategies for addressing these complex health challenges. The overlap with addiction treatment offers a valuable lesson: once we reduce stigma and prioritize evidence-based care, we can make significant progress in improving public health.

Ongoing Surveillance and Guidance Updates: The FDA and other regulatory bodies will continue to monitor the safety and efficacy of GLP-1 agonists, and guidance may be updated as new evidence emerges. Individuals considering these medications should discuss the potential benefits and risks with a qualified healthcare professional.